biostudies-literatureSantonocito DProject Piaceri "Valutazione degli Effetti del Trattamento con Diroximel Fumarato in Nanoparti-celle Lipidiche Solide (DRF-SLN) per via Intranasale in Modelli Murini di Sclerosi Multipla, (MS-NANOTECH)". UPB: 57722172155.11827https://www.ebi.ac.uk/biostudies/studies/S-EPMC12732671biostudies-literatureUnknown26(24)Diroximel fumarate (DRF) is an orally administered prodrug used in multiple sclerosis (MS) treatment. Although it exhibits better gastrointestinal (GI) tolerability than its analogues, many patients still discontinue therapy due to frequent GI adverse events. To overcome these limitations, alternative drug delivery systems that bypass the GI tract are needed. Direct nose-to-brain delivery represents a promising approach to circumvent the blood-brain barrier and target the central nervous system; however, limited nasal mucosal absorption and the small volume of the nasal cavity pose significant challenges. Solid lipid nanoparticles (SLNs) can potentially overcome these obstacles by enhancing drug bioavailability and protecting against enzymatic degradation. This research aimed to develop anInternational journal of molecular sciencesDiroximel Fumarate-Loaded Solid Lipid Nanoparticles (DRF-SLNs) as Potential Carriers for the Treatment of Multiple Sclerosis: Preformulation Study.PMC12732671Project Piaceri "Valutazione degli Effetti del Trattamento con Diroximel Fumarato in Nanoparti-celle Lipidiche Solide (DRF-SLN) per via Intranasale in Modelli Murini di Sclerosi Multipla, (MS-NANOTECH)". UPB: 57722172155.Sarpietro MGMangano KSantonocito DSciacca CPuglia CRomeo GSchoubben AGreco GfalseDiroximel Fumarate-Loaded Solid Lipid Nanoparticles (DRF-SLNs) as Potential Carriers for the Treatment of Multiple Sclerosis: Preformulation Study.Diroximel fumarate (DRF) is an orally administered prodrug used in multiple sclerosis (MS) treatment. Although it exhibits better gastrointestinal (GI) tolerability than its analogues, many patients still discontinue therapy due to frequent GI adverse events. To overcome these limitations, alternative drug delivery systems that bypass the GI tract are needed. Direct nose-to-brain delivery represents a promising approach to circumvent the blood-brain barrier and target the central nervous system; however, limited nasal mucosal absorption and the small volume of the nasal cavity pose significant challenges. Solid lipid nanoparticles (SLNs) can potentially overcome these obstacles by enhancing drug bioavailability and protecting against enzymatic degradation. This research aimed to develop an2025-01-01T00:00:00Z2025 Dec2026-05-27T12:18:34.488Z2026-05-27T03:12:07.367ZS-EPMC127326714146525710.3390/ijms262411827